Living with moderate to severe asthma can be challenging, with frequent flare-ups making it hard to breathe and enjoy life. A new study is evaluating a drug called brenipatide to see if it can help adults with this condition. The study will last about 65 weeks and will compare different doses of brenipatide to a placebo, which is a treatment that doesn’t contain an active drug. The main goal is to measure how often asthma flare-ups occur over a year of treatment. With an estimated 531 participants, this research could provide valuable insights into a new option for those struggling to control their asthma. If brenipatide proves effective, it might lead to better control of symptoms and improved quality of life for many people.
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe AsthmaCould a new drug help people with severe asthma breathe easier?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Evaluate brenipatide's impact on asthma exacerbation rates over 52 weeks.
This Phase 2 study, sponsored by Eli Lilly and Company, is currently recruiting participants to evaluate the safety and efficacy of brenipatide in adults with uncontrolled moderate-to-severe asthma. The trial will compare different dose levels of brenipatide against a placebo. A total of 531 participants are estimated to enroll, with the study spanning approximately 65 weeks, including screening, treatment, and follow-up periods. The primary outcome measure is the annualized asthma exacerbation rate over 52 weeks of treatment. The study began on October 22, 2025, with a primary completion date set for April 2028. This trial aims to provide insights into the potential benefits of brenipatide for asthma management.
What this means for you:
Brenipatide is being tested to see if it can reduce asthma flare-ups in adults with severe asthma. More on Asthma
Oral bacterial lysates reduce wheezing frequency and infection rates in children with asthma
Oral bacterial lysates may improve outcomes for children with asthma
This meta-analysis of 2,893 children with asthma found that oral bacterial lysates (OBLs) significantly reduced wheezing frequency (MD = -3.…
A review of data suggests that oral bacterial lysates could reduce wheezing and infection rates in children living with asthma.
Polygenic risk scores validate IL-1 signaling role in childhood asthma, supporting IL1R1 antagonist repurposing
New data links specific proteins to asthma risk in children
This meta-analysis of two family-based cohorts found that externally derived asthma polygenic risk scores (GBMI-PRS) are valid in children a…
Researchers found that certain genetic markers and protein levels can help identify the underlying causes of childhood asthma.
Pharmacist-led telepharmacy may improve medication adherence and reduce blood pressure in patients with NCDs
Pharmacist Led Telepharmacy May Improve Medication Adherence For Chronic Illness
This systematic review analyzed 21 trials involving 5440 participants to evaluate pharmacist-led telepharmacy for managing non-communicable …
Remote pharmacist services through phone or video may help patients with high blood pressure and diabetes stick to their daily medication pl…
Structured physical activity improves FEV1% predicted by 5.79 and PAQLQ scores in patients with asthma
Structured Physical Activity Shows Benefits for People with Asthma
This meta-analysis of trials involving structured physical activity for at least 6 weeks found significant improvements in FEV1% predicted (…
Structured physical activity programs of at least 6 weeks may improve lung function and quality of life for people living with asthma.
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Asthma
Intervention(s): Brenipatide (DRUG), Brenipatide (DRUG), Placebo (DRUG)
The purpose of this study is to assess the safety and efficacy of brenipatide at different dose levels compared with placebo in participants with moderate-to-severe asthma.
Study participation will last approximately 65 weeks, including screening, treatment, and follow-up periods.
Primary Outcome(s): Annualized Asthma Exacerbation Rate Over 52 Weeks of Treatment
Enrollment: 531 (ESTIMATED)
Lead Sponsor: Eli Lilly and Company
Start: 2025-10-22 | Primary Completion: 2028-04
Budesonide-glycopyrronium-formoterol fumarate dihydrate improved lung function and reduced severe exacerbations versus budesonide-formoterol in inadequately controlled asthma
New Asthma Drug Cuts Attacks Without Recent Crisis
Related in Allergy & Immunology
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
FDA Approves Exdensur for Add-On Maintenance Treatment of Severe Eosinophilic Asthma
FDA approves new long-acting shot Exdensur for severe asthma.
FDA approved Exdensur (IL-5 antagonist) for add-on maintenance treatment of severe eosinophilic asthma in patients aged 12 years and older. …
The FDA approved Exdensur as an add-on treatment for severe asthma in people 12 and older. It is given as a shot every six months. This new …
CD8+ T cells and associated signaling pathways influence osteoclast formation and osteoblast differentiation in osteoporosis
Immune Cells and Signaling Pathways Influence Bone Health in Osteoporosis
This narrative review synthesizes the role of CD8+ T cells and related cytokines like IFN-gamma, CCL5, and IL-33 in bone metabolism. The aut…
New research highlights how specific immune cells and signaling pathways may play a dual role in protecting or promoting bone loss in osteop…
E3 ubiquitin ligases modulate SARS-CoV-2 replication and immune evasion through targeted protein degradation mechanisms
SARS-CoV-2 uses host enzymes to hide from the immune system
This mini-review explores the role of E3 ubiquitin ligases in the context of SARS-CoV-2 infection. The authors synthesize how these enzymes …
New research shows how the virus hijacks specific proteins in our cells to replicate and dodge our body's natural defenses.
From Other Specialties
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …
Rapid advancements in imaging and blood-based biomarkers are transforming the diagnosis and management of ADRD
New guidelines help doctors tell delirium from dementia
This clinical guideline provides a narrative review on the evolving diagnostic and treatment landscape for Alzheimer's disease and related d…
Delirium is acute and fluctuating; dementia is chronic. New guidelines help doctors tell them apart.
ACTH and vigabatrin achieved full seizure control in a patient with Ververi-Brady syndrome
ACTH and Vigabatrin Show Promise for Rare Epilepsy Syndrome
This case report describes a 5-month-old male infant with Ververi-Brady syndrome and infantile epileptic spasms syndrome. The patient achiev…
A new gene variant linked to Ververi-Brady syndrome showed positive results when treated with a combination of ACTH and vigabatrin.
Postoperative AKI occurs in half of type A aortic dissection surgeries, meta-analysis finds
Factors Linked to Kidney Injury After Aortic Dissection Surgery
This meta-analysis of 44 studies (11,983 patients) found that 50.72% of patients undergoing surgery for Stanford type A aortic dissection de…
Over half of patients undergoing surgery for a specific type of aortic dissection develop acute kidney injury, with several risk factors ide…